{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:13Z","timestamp":1787026513537,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The prevalence of obesity in general pediatric population increases without sparing children with T1D. We intended to find factors associated with the possibility of preserving endogenous insulin secretion in individuals with long-standing T1D. At onset, higher BMI is associated with higher C-peptide level, which may indicate to be one of the favorable factors involved in preserving residual \u03b2-cell function. The study determines the influence of BMI on C-peptide secretion in children newly diagnosed with T1D in two years observation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed the possible relationship between selected pro- and anti-inflammatory cytokines, body mass at recognition and \u03b2-cell function status. 153 pediatric patients with newly diagnosed T1D were divided into quartiles according to BMI-SDS index. We separated a group consisted of patients with BMI-SDS &amp;gt;1. Participants were followed up for two years and examined for changes in body weight, HbA1c, and insulin requirement. C-peptide was assessed at baseline and after two years. We evaluated the patients\u2019 levels of selected inflammatory cytokines at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subjects with higher BMI-SDS presented higher serum C-peptide levels and lower insulin requirements at diagnosis than children with lower body weight. The two-year follow-up showed that C-peptide levels of obese patients dropped more rapidly than in children with BMI-SDS within normal limits. The group with BMI-SDS &amp;gt;1 showed the greatest decrease in C-peptide level. Despite statistically insignificant differences in HbA1c at diagnosis between the study groups, in the fourth quartile and BMI-SDS &amp;gt;1 groups, HbA1c as well as insulin requirements increased after two years. The levels of cytokines varied the most between BMI-SDS &amp;lt;1 and BMI-SDS &amp;gt;1 groups and were significantly higher within BMI-SDS &amp;gt;1 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Higher BMI, associated with enhanced levels of inflammatory cytokines, relates to preservation of C-peptide at T1D recognition in children but is not beneficial in the long term. A decrease in C-peptide levels combined with an increase in insulin requirements and in HbA1c among patients with high BMI occur, which may indicate a negative effect of excessive body weight on the long term preservation of residual \u03b2-cell function. The process seems to be mediated by inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1176403","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T01:27:29Z","timestamp":1682558849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Excessive BMI is associated with higher C-peptide level at recognition but also with its greater loss in two years clinical observation in children with new onset type 1 diabetes"],"prefix":"10.3389","volume":"14","author":[{"given":"Emilia","family":"Kurpiewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ci\u0119\u017cki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Jamio\u0142kowska-Sztabkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Polkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Starosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Grubczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Moniuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Bossowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"G\u0142owi\u0144ska-Olszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4274\/Jcrpe.1471","article-title":"Overweight and obesity in children and adolescents","volume":"6","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"109083","DOI":"10.1016\/j.diabres.2021.109083","article-title":"Global estimates of incidence of type 1 diabetes in children and adolescents: results from the international diabetes federation atlas, 10","volume":"183","author":"Ogle","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12730","article-title":"Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: data from the international SWEET registry","volume":"19","author":"Maffeis","year":"2018","journal-title":"Pediatr Diabetes."},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diabres.2017.01.012","article-title":"Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D exchange clinic registry","volume":"126","author":"Minges","year":"2017","journal-title":"Diabetes Res Clin Practice."},{"key":"B5","doi-asserted-by":"publisher","first-page":"107513","DOI":"10.1016\/j.jdiacomp.2019.107513","article-title":"Overweight and obese children with optimal control in the T1D exchange registry: how are they different from lean children with optimal control","volume":"34","author":"Flokas","year":"2020","journal-title":"J Diabetes Complications"},{"key":"B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11892-017-0918-8","article-title":"Weight management in patients with type 1 diabetes and obesity","volume":"17","author":"Mottalib","year":"2017","journal-title":"Curr Diabetes Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.1.250","article-title":"C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001","volume":"53","author":"Palmer","year":"2004","journal-title":"Diabetes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0871","article-title":"Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors","volume":"38","author":"Oram","year":"2015","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5114\/pedm.2021.107165","article-title":"C-peptide and residual \u03b2-cell function in pediatric diabetes - state of the art","volume":"27","author":"Jamio\u0142kowska-Sztabkowska","year":"2021","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12850","article-title":"Low levels of c-peptide have clinical significance for established type 1 diabetes","volume":"32","author":"Kuhtreiber","year":"2015","journal-title":"Diabetes Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3559-y","article-title":"CGM-measured glucose values have a strong correlation with c-peptide, HbA1c and IDAAC, but do poorly in predicting c-peptide levels in the two years following onset of diabetes","volume":"58","author":"Buckingham","year":"2015","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3067-x","article-title":"The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells","volume":"57","author":"Oram","year":"2014","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-543X.2004.00034.x","article-title":"Redefining the clinical remission period in children with type 1 diabetes","volume":"5","author":"Chase","year":"2004","journal-title":"Pediatr Diabetes."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5114\/pedm.2019.84709","article-title":"Clinical determinants of the remission phase in children with new-onset type 1 diabetes mellitus in two years of observation","volume":"25","author":"Rydzewska","year":"2019","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12734","article-title":"ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents","author":"Couper","year":"2018","journal-title":"Pediatr Diabetes."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13018","article-title":"Regular physical activity as a physiological factor contributing to extend partial remission time in children with new onset diabetes mellitus-two years observation","volume":"21","author":"Jamio\u0142kowska-Sztabkowska","year":"2020","journal-title":"Pediatr Diabetes."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0100","article-title":"Markers influencing the presence of partial clinical remission in patients with newly diagnosed type 1 diabetes","volume":"30","author":"Pyziak","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12609","article-title":"The influence of body mass index and age on c-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1","volume":"19","author":"Sosenko","year":"2018","journal-title":"Pediatr Diabetes."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12159","article-title":"Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes","volume":"15","author":"Redondo","year":"2014","journal-title":"Pediatr Diabetes."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2340","article-title":"Obesity, islet cell autoimmunity, and cardiovascular risk factors in youth at onset of type 1 autoimmune diabetes","volume":"100","author":"Cedillo","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2015.20.2.92","article-title":"Preserved c-peptide levels in overweight or obese compared with underweight children upon diagnosis of type 1 diabetes mellitus","volume":"20","author":"Yu","year":"2015","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0522","article-title":"BMI is an important driver of \u03b2-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children","volume":"172","author":"Lauria","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa715","article-title":"Factors associated with the decline of c-peptide in a cohort of young children diagnosed with type 1 diabetes","volume":"106","author":"Steck","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.02.103","article-title":"The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus","volume":"101","author":"Abdel-Moneim","year":"2018","journal-title":"BioMed Pharmacother."},{"key":"B26","article-title":"Serum levels of tumor necrosis factor alpha and interleukine-12 in some Iraqi diabetic patients Type1","volume":"3","author":"Saud","year":"2014","journal-title":"International Journal of Current Microbiology and Applied Sciences"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0176157","DOI":"10.1371\/journal.pone.0176157","article-title":"The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"12","author":"Qiao","year":"2017","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107765","DOI":"10.1016\/j.intimp.2021.107765","article-title":"Interleukin-1 in obesity-related low-grade inflammation: from molecular mechanisms to therapeutic strategies","volume":"96","author":"Ghanbari","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/jcm11051303","article-title":"IL-1\u03b2 implications in type 1 diabetes mellitus progression: systematic review and meta-analysis","volume":"11","author":"Cano-Cano","year":"2022","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13454","article-title":"ISPAD clinical practice consensus guidelines 2022: definition, epidemiology, and classification of diabetes in children and adolescents","volume":"23","author":"Libman","year":"2022","journal-title":"Pediatr Diabetes."},{"key":"B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00431-010-1329-x","article-title":"Polish 2010 growth references for school-aged children and adolescents","volume":"170","author":"Ku\u0142aga","year":"2011","journal-title":"Eur J Pediatr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958430","article-title":"Immunological balance between treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children","volume":"13","author":"Starosz","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.03.009","article-title":"Factors associated with preservation of c-peptide levels at the diagnosis of type 1 diabetes","volume":"32","author":"Szypowska","year":"2018","journal-title":"J Diabetes Complications."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2012.00875.x","article-title":"Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes","volume":"13","author":"Redondo","year":"2012","journal-title":"Pediatr Diabetes."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.03.003","article-title":"Decline of c-peptide during the first year after diagnosis of type 1 diabetes in children and adolescents","volume":"100","author":"Ludvigsson","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2017.53.3.216","article-title":"Factors associated with c-peptide levels after diagnosis in children with type 1 diabetes mellitus","volume":"53","author":"Hwang","year":"2017","journal-title":"Chonnam Med J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s001250100548","article-title":"The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes","volume":"44","author":"Wilkin","year":"2001","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.890833","article-title":"Multi-faceted influence of obesity on type 1 diabetes in children - from disease pathogenesis to complications","volume":"13","author":"Ci\u0119\u017cki","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.97","article-title":"The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes","volume":"33","author":"Wilkin","year":"2009","journal-title":"Int J Obes (Lond)."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of c-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabetes Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0265-4","article-title":"A practical review of c-peptide testing in diabetes","volume":"8","author":"Leighton","year":"2017","journal-title":"Diabetes Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4274\/jcrpe.2017.S005","article-title":"Insulin resistance, prediabetes, metabolic syndrome: what should every pediatrician know","volume":"9","author":"Ighbariya","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2020.4982","article-title":"Role of inflammatory cytokines in obese and nonobese diabetic children","volume":"8","author":"Abdelhamid","year":"2020","journal-title":"Open Access Macedonian J Med Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/nu12051305","article-title":"Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance","volume":"12","author":"Kojta","year":"2020","journal-title":"Nutrients"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.63.s84.50.x","article-title":"Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease","author":"Zoccali","year":"2003","journal-title":"Kidney Int Suppl."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2018.33.1","article-title":"The role of inflammation in diabetes: current concepts and future perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur Cardiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1167","article-title":"Excess BMI accelerates islet autoimmunity in older children and adolescents","volume":"43","author":"Ferrara-Cook","year":"2020","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1061671","article-title":"Autoimmune reaction against pancreatic beta cells in children and adolescents with simple obesity","volume":"13","author":"Chyli\u0144ska-Fr\u0105tczak","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01847-y","article-title":"Teplizumab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1727885","article-title":"CTLA4-ig (abatacept): a promising investigational drug for use in type 1 diabetes","volume":"29","author":"Rachid","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and beta-cell function in youth with new-onset type 1 diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2365","article-title":"Residual beta cell function at diagnosis of type 1 diabetes in children and adolescents varies with gender and season","volume":"29","author":"Samuelsson","year":"2013","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1176403\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T01:27:32Z","timestamp":1682558852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1176403\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2023.1176403"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1176403","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1176403"}}